

Veradigm. Metabolic Registry Program Measures

Measure ID	Measure Description	Developer	NQF #
Meta 1	Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c>9.0% during the measurement period	NCQA	0059
Meta 2	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%): Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease and diabetes seen within a 12-month period who have a current or prior LVEF < 40% who were prescribed an ACE inhibitor or ARB therapy	ACCF	
Meta 3	Diabetes: Medical Attention for Nephropathy: Percentage of patients 18-75 years of age with diabetes who had nephropathy screening test or evidence of nephropathy during the measurement period	NCQA	
Meta 4	Tobacco Use: Screening and Cessation Intervention: Percentage of patients aged 18 years and older with diabetes who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user	ACCF/AHA/PCPI	
Meta 5	Dietary Intake Counseling: Percentage of patients aged 18 and older with diabetes who were counseled to eat a healthy diet	ACCF/AHA	
Meta 6	Physical Activity Counseling: Percentage of patients aged 18 and older with diabetes who were counseled to engage in regular physical activity	ACCF/AHA	
Meta 7	Peripheral Artery Disease (PAD): Treatment of Blood Cholesterol to Reduce Atherosclerotic Risk: Percentage of patients 18-75 years of age with PAD and diabetes who were offered moderate-to-high intensity statin	ACCF/AHA/PCPI	
Meta 8	Diabetes Eye Exam (retinal) Performed: Percentage of patients aged 18 and older with diabetes who received an eye exam	NCQA	0055
Meta 9	Diabetes Foot Exam: Percentage of patients aged 18 and older with diabetes who received a foot exam	NCQA	0056
Meta 10	Diabetes Advance Care Plan: Percentage of patients aged 65 years and older with diabetes and who have an advance care plan or surrogate decision marker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan	ACCF/AHA/PCPI	
Meta 11	Antiplatelet Therapy: Percentage of patients aged 18 and older with diabetes who received antiplatelet therapy to reduce the risk of myocardial infarction, stroke, or vascular death in patients with a history of symptomatic PAD	ACCF/AHA/ ACR/SCAI/ SIR/ SVM/ SVN/SVS	

Measure ID	Measure Description	Developer	NQF #
Meta 13	Coronary Artery Disease (CAD): Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Percentage of patients ages 18-75 with CAD and diabetes who were offered moderate-to-high intensity statin	ACCF/AHA/ AMA-PCPI	
Meta 15	Hypertension: Blood Pressure Treatment and Control for High-Risk Patients: Proportion of adults ≥18 years of age with both hypertension and diabetes who were prescribed antihypertensive medication or who had adequately controlled blood pressure	ACCF	

Metabolic Registry participants include clinicians in primary care, endocrinology, and cardiology ambulatory care settings. Eligible providers must be able to report 7 of the measures listed above to participate in the Metabolic Collaborative Registry.



Metabolic Registry is a Veradigm Network solution

© 2023 Veradigm Inc. and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm Inc. and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved. VDMP516-2 February 2023